NASDAQ | TSX: ACB EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025. 11 1 "Aurora has established a commanding leadership position within the rapidly expanding, high margin, global medical cannabis market. We achieved record quarterly net revenue of $76.2 million in our globa ...

Core Insights - Aurora Cannabis Inc. has been recognized in the Globe & Mail's 2025 Report on Business as an honouree in the Women Lead Here list, highlighting its commitment to gender diversity at the executive level [1][3] - The company boasts that 43% of its executive leadership team consists of women, emphasizing their role in driving change within the medical cannabis industry [2][3] - Aurora established the Women Empowerment Network (WEN) in 2022 to support the advancement of women within the organization, offering learning and community engagement opportunities [2] Company Overview - Aurora Cannabis Inc. is a leading global medical cannabis company based in Edmonton, Alberta, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [4] - The company's product portfolio includes various adult-use brands such as Drift, San Rafael '71, and medical cannabis brands like MedReleaf and CanniMed, among others [4] - Aurora is also a major player in the agricultural sector with a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants [4] Market Presence - Aurora's common shares are traded on NASDAQ and TSX under the symbol "ACB," indicating its established presence in the financial markets [5]

Core Insights - Aurora Cannabis Inc. is participating as a leader in the inaugural Global Cannabis Regulatory Summit (GCRS) in Washington, D.C. on March 26-27, 2025, highlighting its role in advocating for policy reform in the cannabis industry [1][2] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of adult-use brands including Drift, San Rafael '71, Daily Special, Tasty's, Being, and Greybeard, as well as medical cannabis brands such as MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. [3] - Aurora also holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [3] Industry Engagement - The GCRS will facilitate discussions among regulators, members of Congress, international policy experts, and cannabis industry executives to shape the future of the global cannabis industry [2][3] - Aurora's participation in panel discussions aims to enhance understanding of the distinctions between medical and adult-use cannabis, informed by international political and regulatory consensus [3]

Core Insights - Aurora Cannabis Inc. has discovered a novel source of genetic resistance against powdery mildew (PM2), which will enhance the protection of cannabis sativa against this pathogen [1][3] - The proprietary genetic marker technology developed will be integrated into Aurora's breeding program, aiming for commercial launch of powdery mildew resistant cultivars within the year [1][2] Industry Impact - This discovery addresses a significant challenge in the global cannabis industry, providing a sustainable solution for disease management and enhancing agricultural productivity [2][3] - The advancement in genetic research positions Aurora as a leader in the cannabis sector, differentiating it from competitors by focusing on scientific excellence and innovation [2][4] Research Collaboration - The research was led by Principal Scientist Jose Celedon in collaboration with The University of British Columbia, emphasizing the importance of breeding genetic resistance for sustainable agriculture [3][11] - The findings are documented in a peer-reviewed article, highlighting the scientific rigor behind the discovery [5][11] Business Strategy - Aurora's commitment to scientific research and innovation has resulted in improved potency and yield, ultimately reducing production costs and increasing efficiency [4] - The company aims to enhance biosecurity, reduce costs, and improve product quality through this genetic advancement, creating new market opportunities [3][9]